埃克替尼在伴有 EGFR 敏感突变Ⅱ~ⅢA期非小细胞肺癌术后辅助治疗的应用

The Application of Icotinib as Adjuvant Therapy for StageⅡ~ⅢA EGFR⁃Mutant Non-Small-Cell Lung Cancer

1文献来源He J,Su C,Liang W,et al.Icotinib versus chemotherapy as adjuvant treatment for stageⅡ-ⅢA EGFR-mutant non-small-cell lung cancer(EVIDENCE):A randomised,open-label,phase 3 trial[J].Lancet Respir Med,2021,9(9):1021-1029.2证据水平1a。3背景以铂类为基础的辅助化疗是Ⅱ~ⅢA期非小细胞肺癌(non-small-cell lung cancer,NSCLC)患者的标准治疗方案。